达格列净对经皮冠状动脉介入治疗后急性心肌梗死合并2型糖尿病患者的心功能和预后影响

摘要/Abstract

摘要： 目的探讨达格列净对经皮冠状动脉介入(PCI)治疗后急性心肌梗死（AMI）合并2型糖尿病（T2DM）患者的心功能及预后的影响。方法选取2019年1月到2023年5月本院169例经皮冠状动脉介入治疗后急性心肌梗死合并2型糖尿病患者临床资料进行回顾性研究,根据出院时是否使用达格列净分为研究组90例（达格列净组）和对照组79例（无达格列净组）。比较两组患者治疗前后左室舒张末期内径（LVEDD）、左室收缩末期内径（LVESD）、左室射血分数（LVEF）和心血管不良事件[包括全因死亡、心力衰竭（HF）、非致死性心肌梗死、非致死性脑卒中、非计划外血运重建（URR）]情况。结果治疗后两组患者的LVEDD、LVESD均低于治疗前,且研究组低于对照组,治疗后两组患者的LVEF均高于治疗前,且研究组高于对照组,差异有统计学意义（P<0.05）。治疗后两组患者在全因死亡、非致死性脑卒中、非致死性心肌梗死等不良事件方面差异无统计学意义（P>0.05）。但研究组心血管不良事件、心力衰竭、非计划外血运重建发生率低于对照组（P<0.05）。Kaplan-Meier生存分析曲线显示研究组在MACE（P=0.032）、HF（P=0.034）、URR（P=0.043）的中位生存时间比对照组更高（P<0.05）。结论达格列净可在一定程度上改善经皮冠状动脉介入治疗后急性心肌梗死合并2型糖尿病患者的心功能和预后,降低心血管不良事件、心力衰竭、非计划外血运重建发生率。

关键词: 急性心肌梗死, 2型糖尿病, 达格列净, 心功能, 预后

蓝淦秋, 于佳雪, 陈利华, 黄思慧. 达格列净对经皮冠状动脉介入治疗后急性心肌梗死合并2型糖尿病患者的心功能和预后影响[J]. 心血管病防治知识, 2024, 14(14): 41-45.

参考文献

[1] 赵茂荪. 急性心肌梗死的相关危险因素分析[J],2017,21(17):2218-2219.
[2] 曾庆虹,张晓妍.急性心肌梗死合并2型糖尿病患者的生化指标及冠状动脉病变特点分析[J].江苏医药,2021,47(01):66-68,72.
[3] Wiviott SD, Raz I,Bonaca MP,etal. The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial.Am Heart J.2018;200:83-89.
[4] Liu X, Zhang S, Chen K, etal. Preventative effects of dapagliflozin on early ventricular dysfunction and remodeling in patients with acute anterior STEMI - The PREDOMINACE trial. Am Heart J Plus.2022 Jul 16;18:100181. doi: 10.1016/j.ahjo.2022.100181. PMID: 38559420; PMCID: PMC10978327.
[5] 中国医师协会急诊医师分会,国家卫健委能力建设与继续教育中心急诊学专家委员会,中国医疗保健国际交流促进会急诊急救分会.急性冠脉综合征急诊快速诊治指南(2019)[J].中华急诊医学杂志,2019,28(4):421-428.
[6] 中国2型糖尿病防治指南(2020年版)(上)[J].中国实用内科学志,2021,41(8):668-695.
[7] Estep JD, Aguilar D. Diabetes and heart failure in the post-myocardial infarction patient. Curr Heart Fail Rep.2006 Dec;3(4):164-9.
[8] Chun BY, Dobson AJ, Heller RF.The impact of diabetes on survival among patients with first myocardial infarction. DiabetesCare.1997May;20(5):704-8.
[9] Furtado RHM, Bonaca MP, Raz I, etal. Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction. Circulation.2019 May28;139(22):2516-2527.
[10] Mao L, Cai D, Chi B, etal. Dapagliflozin reduces risk of heart failure rehospitalization in diabetic acute myocardial infarction patients: a propensity score-matched analysis. Eur J Clin Pharmacol.2023 Jul;79(7):915-926.
[11] Zhou L, Geng X, Hu Q,etal. Effects of dapagliflozin on cardiac function and short-term prognosis of patients with both acute myocardial infarction and type 2 diabetes mellitus. Minerva Cardiol Angiol.2024 Jun;72(3):292-298.
[12] Hallow KM, Greasley PJ, Helmlinger G, etal. Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data. Am J Physiol Renal Physiol.2018 Nov 1;315(5):F1295-F1306.
[13] Shi L, Zhu D, Wang S, etal. Dapagliflozin Attenuates Cardiac Remodeling in Mice Model of Cardiac Pressure Overload. Am J Hypertens.2019 Apr 22;32(5):452-459.
[14] 杜阳阳,崔勇波,李海芹.急性心肌梗死PCI术后主要不良心血管事件的发生率及影响因素[J].深圳中西医结合杂志,2023,33(22):118-121.
[15] Donnan PT, Boyle DI, Broomhall J, etal. Prognosis following first acute myocardial infarction in Type 2 diabetes: a comparative population study. Diabet Med.2002 Jun;19(6):448-55.
[16] Gruppetta M, Calleja N, Fava S. Long-term survival after acute myocardial infarction and relation to type 2 diabetes and other risk factors. Clin Cardiol.2010 Jul;33(7):424-9.
[17] Zhu Y, Zhang JL, Yan XJ,etal. Effect of dapagliflozin on the prognosis of patients with acute myocardial infarction undergoing percutaneous coronary intervention. Cardiovasc Diabetol.2022 Sep 16;21(1):186.
[18] Carvalho LSF Quinaglia T; ADDENDA-BHS2 trial investigators. Dapagliflozin effect on endothelial dysfunction in diabetic patients with atherosclerotic disease: a randomized active-controlled trial. Cardiovasc Diabetol.2021 Mar 26;20(1):74.
[19] Wang C, Qin Y, Zhang X, etal. Effect of Dapagliflozin on Indicators of Myocardial Fibrosis and Levels of Inflammatory Factors in Heart Failure Patients. Dis Markers. 2022 Sep 5;2022:5834218.
[20] Joshi SS, Singh T, Newby DE, etal. Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure. Heart.2021 Jun 11;107(13):1032-1038.